Global Genome Engineering Market, by Technology (CRISPR, TALEN, ZFN, and others), by Application (Cell Line Engineering, and Genetic Engineering), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organizations) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5.21 billion in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing development of novel technologies in genome engineering is expected to be major driving factor for growth of global genome engineering market over the forecast period. For instance, in 2017, Synthego Corporation, a U.S.-based company of genome engineering solutions, launched its CRISPRevolution Gene Knockout Kit (GKO), with the first guaranteed CRISPR gene editing solution. The new Synthego's kit rapidly modifies difficult-to-edit human hematopoietic stem cells, as well as primary T cells, in a cost-effective manner. In 2017, Thermo Fisher Scientific, a U.S.-based player launched its expanded Invitrogen TrueEdit genome editing toolkit. This new kit aims to address the full spectrum of genome editing needs like enzymes that act on DNA called nucleases.
Global Genome Engineering Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global genome engineering market, owing to an increase in demand of genome engineering technology for COVID-19 diagnostic tests. For instance, in December 2020, according to an article published by Springer Nature Limited, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR-associated) systems have improved ability to edit genes and modulate gene expression. The mechanism naturally defends bacteria against invading bacteriophages and other foreign nucleic acids. Deoxyribonucleic Acid (DNA)-targeting effectors such as Cas9 ensure protection against DNA bacteriophages, and Ribonucleic Acid-RNA-targeting activity for type III and VI effectors provide defense against RNA pathogens. This suggests that CRISPR effectors could be reprogrammed to aid mammalian cells defending against both DNA and RNA viruses. Indeed, recent Cas9 applications have demonstrated that CRISPR effectors can suppress replication of double-stranded DNA viruses or singlestranded RNA (ssRNA) viruses with DNA intermediates in mammalian cells. The recent coronavirus (COVID-19) outbreak presents enormous difficulties for global health. Zhang et al. has developed a research protocol along with the CRISPRCas13 based diagnostics for SARS-CoV-2. The described research techniques provide the basic framework to set up Sherlock-based COVID-19 tests by using paper strips. Sherlock system is based on the CRISPR-Cas13 and can detect specifically different RNA viruses in patient specimens.
Global Genome Engineering Market: Key Developments
On May 16 2022, according to an article published by PubMed, A team of Georgia State University researchers led by Regents' Professor of Neuroscience H. Elliott Albers and distinguished university professor Kim Huhman used CRISPR-Cas9 technology to eliminate the actions of a neurochemical signaling pathway that plays a critical role in regulating social behaviors in mammals. Vasopressin and the receptor that it acts on called Avpr1a regulates social phenomena ranging from pair bonding, cooperation, and social communication to dominance and aggression. The new study, published in the Proceedings of the National Academy of Sciences (PNAS), finds that knocking out the Avpr1a receptor in hamsters, and thus effectively eliminating vasopressin's action on it, dramatically altered the expression of social behavior in unexpected ways.
Browse 47 Market Data Tables and 42 Figures spread through 185 Pages and in-depth TOC on “Global Genome Engineering Market”- Forecast to 2030, Global Genome Engineering Market, by Technology (CRISPR, TALEN, ZFN, and Others), by Application (Cell Line Engineering, and Genetic Engineering), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Genome Engineering Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/genome-engineering-market-1262
Moreover, increasing development of novel technologies in genome engineering is expected to be major driving factor for growth of global genome engineering market over the forecast period. For instance, in January 2018, Synthego Corporation, a U.S.-based company offering genome engineering solutions, launched its new CRISPR Analysis Software, Inference of CRISPR Edits (ICE). Inference of CRISPR Edits is a free to use and open-source software, and the only CRISPR analysis software for batch processing of sanger data. The launches of such novel genome engineering technologies is expected to create a conducive environment for growth of global genome engineering market.
Key Takeaways of the Global Genome Engineering Market:
- Global genome engineering market is expected to exhibit a CAGR of 14.3% during the forecast period due to the increasing research and development of genome engineering by key players. For instance, on March 29, 2022, Promega Corporation, a company that is a manufacturer of enzymes and other products for biotechnology and molecular biology to Launch Post-Doctoral Research Program to Develop New Tools for Genome Editing. MADISON, Wis, Life science researchers can explore new ideas for genome engineering technology through a newly announced post-doctoral research program launched by Promega with mentoring support from AstraZeneca. The program gives researchers the unique opportunity to work on groundbreaking projects in an emerging field while collaborating with scientists at a global pharmaceutical company and a manufacturer of life science research tools.
- Among technology, the CRISPR segment is estimated to hold a dominant position in the global genome engineering market over the forecast period, owing to increased research and development of genome engineering. For instance, on May 23, 2022, according to data published by PubMed, scientists from the University of Maryland College of Agriculture and Natural Resources, have developed CRISPR-Combo, a method to edit multiple genes in plants while simultaneously changing the expression of other genes. This new tool will enable genetic engineering combinations that work together to boost functionality and improve breeding of new crops.
- Among regions, North America was the dominant region in the global genome engineering market and is expected to retain its dominance over the forecast period (2017–2030). This is due to presence of major key players in the region and increasing research and development activities for development of novel genome engineering technologies. For instance, in 2017, Integrated DNA Technologies, Inc., a U.S.-based company, launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR.
- Major players operating in the global genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group
